keyword
MENU ▼
Read by QxMD icon Read
search

"Hepatitis c" cost

keyword
https://www.readbyqxmd.com/read/29343250/evaluation-of-health-status-in-patients-with-hepatitis-c-treated-with-and-without-interferon
#1
R Ragusa, G Bertino, A Bruno, E Frazzetto, F Cicciu, G Giorgianni, L Lupo
BACKGROUND: The evolution of technology in healthcare has increased the health care's costs and, the universal healthcare systems, in developed countries, need to ensure proper allocation of resources. Thus, the major issue is assessing the effectiveness of new medical technologies. The evaluation of quality of life in response to new treatments has become a key indicator in chronic conditions for which medical interventions are evaluated not only in terms of increasing the number of expected life years but also in terms of increasing quality of life...
January 17, 2018: Health and Quality of Life Outcomes
https://www.readbyqxmd.com/read/29328682/brief-report-prevalence-of-hepatitis-b-and-c-virus-infections-in-u-s-air-force-basic-military-trainees-who-donated-blood-2013-2016
#2
Douglas F Taylor, Ryan S Cho, Jason F Okulicz, Bryant J Webber, John G Gancayco
Hepatitis B virus (HBV) and hepatitis C virus (HCV) can cause significant morbidity in military service members. Prevalences of HBV and HCV infections among military recruits accessioning into the U.S. Air Force have not previously been described. The Joint Base San Antonio-Lackland Blood Donor Center was queried for the results of HBV and HCV screening tests among all basic military trainees who donated blood between 25 November 2013 and 16 April 2016. Other active and reserve component members were excluded...
December 2017: MSMR
https://www.readbyqxmd.com/read/29316078/occult-hbv-infection-in-hiv-infected-adults-and-evaluation-of-pooled-nat-for-hbv
#3
T R Dinesha, J Boobalan, S Sivamalar, D Subashini, Sunil S Solomon, K G Murugavel, P Balakrishnan, Davey M Smith, S Saravanan
The study aimed to determine the prevalence of occult Hepatitis B virus (HBV) infection among HIV infected persons, and to evaluate the use of a pooling strategy to detect occult HBV infection in the setting of HIV infection. Five hundred and two HIV positive individuals were tested for HBV, occult HBV, and Hepatitis C and D with serologic and nucleic acid testing (NAT). We also evaluated a pooled NAT strategy for screening occult HBV infection among the HIV-positive individuals. The prevalence of HBV infection among HIV positive individuals was 32 (6...
January 6, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29300496/hepcare-europe-bridging-the-gap-in-the-treatment-of-hepatitis-c-study-protocol
#4
Davina Swan, Walter Cullen, Juan Macias, Cristiana Oprea, Alistair Story, Julian Surey, Peter Vickerman, John S Lambert
BACKGROUND: Hepatitis C (HCV) infection is highly prevalent among people who inject drugs (PWID). Many PWID are unaware of their infection and few have received HCV treatment. Recent developments in treatment offer cure rates >90%. However, the potential of these treatments will only be realised if HCV identification among PWID with linkage to treatment is optimised. This paper describes the Hepcare Europe project, a collaboration between five institutions across four member states (Ireland, UK, Spain, Romania), to develop, implement and evaluate interventions to improve the identification, evaluation and treatment of HCV among PWID...
January 4, 2018: Expert Review of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29290175/future-considerations-for-the-evaluation-of-hepatitis-c-virus-treatments-in-pan-genotypic-therapy-for-noncirrhotic-treatment-naive-patients
#5
Martin J Calabrese, Lauren M Hynicka, Magaly Rodriguez de Bittner, Fadia T Shaya
Given the recent approval of the first pan-genotypic chronic hepatitis C virus (HCV) therapy, managed care, health systems, and clinicians will need to evaluate current practices related to essential laboratory assessments used to select therapy. Historically, clinicians and payers required a battery of tests to determine HCV genotype, viral load, degree of fibrosis, and organ function. In light of current and forthcoming approvals of pan-genotypic therapy, clinicians and payers can expect a more competitive marketplace and a downward curve in the price of therapy...
January 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29288595/inpatient-hospital-burden-of-hepatitis-c-diagnosed-patients-with-decompensated-cirrhosis
#6
Scott A McDonald, Hamish A Innes, Esther Aspinall, Peter C Hayes, Maryam Alavi, Heather Valerio, David J Goldberg, Sharon J Hutchinson
BACKGROUND & AIMS: To describe the burden on inpatient hospital resources over time from patients diagnosed with hepatitis C virus (HCV) infection and who have reached the decompensated stage of cirrhosis (DC), as existing estimates of hospital stay in these patients are limited. METHODS: A retrospective longitudinal dataset was formed via record-linkage between the national HCV diagnosis database and inpatient/daycase hospitalisation and death registers in Scotland...
December 30, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/29287992/comorbidity-concomitant-medication-use-of-resources-and-healthcare-costs-associated-with-chronic-hepatitis-c-virus-carriers-in-spain
#7
Antoni Sicras-Mainar, Ruth Navarro-Artieda, Marc Sáez-Zafra
OBJECTIVES: To assess the comorbidity, concomitant medications, healthcare resource use and healthcare costs of chronic hepatitis C virus patients in the Spanish population. PATIENTS AND METHODS: Retrospective, observational, non-interventional study. Patients included were≥18 years of age who accessed medical care between 2010-2013. Patients were divided into 2 groups based on the presence or absence of liver cirrhosis. The follow-up period was 12 months. Main assessment criteria included general comorbidity level (determined by the resource utilisation band score) and prevalence of specific comorbidities, concomitant medications, healthcare resource use and healthcare costs...
December 26, 2017: Gastroenterología y Hepatología
https://www.readbyqxmd.com/read/29283325/emerging-trends-in-non-interferon-based-genotype-specific-antiviral-agents-pharmaceutical-perspectives
#8
Tahir Farooq, Arruje Hameed, Kanwal Rehman, Muhammad Ibrahim, Matloob Ahmed, Tahsin Gulzar, Muhammad Sajid Hamid Akash
Hepatitis C virus (HCV) presents a serious global health threat. Initially, the health-care community mainly focused on interferon (IFN)-based therapeutic options to eradicate HCV, but with the passage of time, these applications became unsuitable due to some serious side effects related to the use of IFN. In recent years, research conducted on different phases of HCV's life cycle has opened a new gateway for the use of a direct-acting new generation of anti-HCV agents. Their safer and ultrarapid response has made possible the introduction of triple therapy and use of IFN-free therapeutic treatment strategies...
2017: Critical Reviews in Eukaryotic Gene Expression
https://www.readbyqxmd.com/read/29274178/assessing-uncertainty-in-the-burden-of-hepatitis-c-virus-comparison-of-estimated-disease-burden-and-treatment-costs-in-the-uk
#9
Finn Gubay, Roisin Staunton, Cornelia Metzig, Ibrahim Abubakar, Peter J White
Hepatitis C virus (HCV) is a major and growing public health concern. We need to know the expected health burden and treatment cost, and understand uncertainty in those estimates, to inform policy-making and future research. Two models that have been important in informing treatment guidelines and assessments of HCV burden were compared by simulating cohorts of individuals with chronic HCV infection initially aged 20, 35, and 50 years. One model predicts that health losses (measured in Quality-Adjusted Life-Years (QALYs)) and treatment costs decrease with increasing initial age of the patients, whilst the other model predicts that below 40 years, costs increase and QALY losses change little with age, and above 40 years they decline with increasing age...
December 23, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29261241/insurance-switching-and-mismatch-between-the-costs-and-benefits-of-new-technologies
#10
David Cutler, Michael Ciarametaro, Genia Long, Noam Kirson, Robert Dubois
OBJECTIVES: Many therapies have immediate costs but delayed benefits. Recent and anticipated transformative therapies may exacerbate these challenges. This study explored whether disconnects between short-term budget impacts and long-term costs and benefits, and among impacts on initial payers, downstream payers, and society, are expected for a range of such therapies and whether they are likely consistent or variable, with implications for potential policy responses. STUDY DESIGN: Modeling...
December 2017: American Journal of Managed Care
https://www.readbyqxmd.com/read/29248530/stability-of-hepatitis-c-virus-rna-and-anti-hcv-antibody-in-air-dried-and-freeze-dried-human-plasma-samples
#11
Amanda Poe, Ngocvien Thi Duong, Kanwar Bedi, Maja Kodani
Diagnosis of hepatitis C virus (HCV) infection is based on testing for antibodies to HCV (anti-HCV), hepatitis C core antigen (HCV cAg) and HCV RNA. To ensure quality control (QC) and quality assurance (QA), proficiency panels are provided by reference laboratories and various international organizations, requiring costly dry ice shipments to maintain specimen integrity. Alternative methods of specimen preservation and transport can save on shipping and handling and help in improving diagnostics by facilitating QA/QC of various laboratories especially in resource limited countries...
December 14, 2017: Journal of Virological Methods
https://www.readbyqxmd.com/read/29244005/ghost-global-hepatitis-outbreak-and-surveillance-technology
#12
Atkinson G Longmire, Seth Sims, Inna Rytsareva, David S Campo, Pavel Skums, Zoya Dimitrova, Sumathi Ramachandran, Magdalena Medrzycki, Hong Thai, Lilia Ganova-Raeva, Yulin Lin, Lili T Punkova, Amanda Sue, Massimo Mirabito, Silver Wang, Robin Tracy, Victor Bolet, Thom Sukalac, Chris Lynberg, Yury Khudyakov
BACKGROUND: Hepatitis C is a major public health problem in the United States and worldwide. Outbreaks of hepatitis C virus (HCV) infections associated with unsafe injection practices, drug diversion, and other exposures to blood are difficult to detect and investigate. Effective HCV outbreak investigation requires comprehensive surveillance and robust case investigation. We previously developed and validated a methodology for the rapid and cost-effective identification of HCV transmission clusters...
December 6, 2017: BMC Genomics
https://www.readbyqxmd.com/read/29240798/the-cost-of-comorbidities-in-treatment-for-hiv-aids-in-california
#13
David S Zingmond, Kodi B Arfer, Jennifer L Gildner, Arleen A Leibowitz
BACKGROUND: Antiretroviral therapy has increased longevity for people living with HIV (PLWH). As a result, PLWH increasingly experience the common diseases of aging and the resources needed to manage these comorbidities are increasing. This paper characterizes the number and types of comorbidities diagnosed among PLWH covered by Medicare and examines how non-HIV comorbidities relate to outpatient, inpatient, and pharmaceutical expenditures. METHODS: The study examined Medicare expenditures for 9767 HIV-positive Californians enrolled in Medicare in 2010 (7208 persons dually covered by Medicare and Medicaid and 2559 with Medicare only)...
2017: PloS One
https://www.readbyqxmd.com/read/29239069/the-antiviral-role-of-zinc-and-metallothioneins-in-hepatitis-c-infection
#14
Scott A Read, Grant Parnell, David Booth, Mark W Douglas, Jacob George, Golo Ahlenstiel
Metallothioneins (MTs) are small, cysteine rich proteins characterized by a high affinity for monovalent and divalent cations, such as copper and zinc. Of the four known metallothionein isoforms, only members of the metallothionein 1 and 2 subfamilies are widely expressed, acting as metal chaperones whose primary role is to mediate intracellular zinc homeostasis. Metallothioneins are potently induced by heavy metals and other sources of oxidative stress where they facilitate metal binding and detoxification as well as free radical scavenging...
December 14, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29223371/planning-and-prioritizing-direct-acting-antivirals-treatment-for-hcv-patients-in-countries-with-limited-resources-lessons-from-the-egyptian-experience
#15
Aisha Elsharkawy, Maissa El Raziky, Wafaa El Akel, Kadry El Saeed, Rasha Eletreby, Mohamed Hassany, Manal Hamdy El-Sayed, Khaled Kabil, Sohier A Ismail, Magdy El-Serafy, Ashraf Omar Abdelaziz, Mohamed Kamal Shaker, Ayman Yosry, Wahid Doss, Yehia El Shazly, Gamal Esmat, Imam Waked
BACKGROUND AND AIM: The introduction of direct acting antivirals for HCV in Egypt led to massive treatment uptake to become the largest HCV treatment program worldwide. The aim of this paper is to present the Egyptian experience in planning and prioritizing mass treatment for HCV patients, highlighting the difficulties and limitations of the program as guide to other countries of similar limited resources. METHODS: Baseline data of 337,042 patients who started treatment from October 2014 to March 2016 were grouped into three equal time intervals of 6 months each...
December 6, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29217468/availability-of-hepatitis-c-diagnostics-and-therapeutics-in-european-and-eurasia-countries
#16
Hakan Leblebicioglu, Joop E Arends, Resat Ozaras, Giampaolo Corti, Lurdes Santos, Christoph Boesecke, Andrew Ustianowski, Ann-Sofi Duberg, Simona Ruta, Nermin N Salkic, Petr Husa, Ivana Lazarevic, Juan A Pineda, Natalia Yurievna Pshenichnaya, Tengiz Tsertswadze, Mojca Matičič, Edmond Puca, Gulzhan Abuova, Judit Gervain, Ramin Bayramli, Salih Ahmeti, Mairi Koulentaki, Badreddine Kilani, Adriana Vince, Francesco Negro, Mustafa Sunbul, Dominique Salmon
BACKGROUND: Treatment with direct acting antiviral agents (DAAs) has provided sustained virological response rates in >95% of patients with chronic hepatitis C virus (HCV) infection. However treatment is costly and market access, reimbursement and governmental restrictions differ among countries. We aimed to analyze these differences among European and Eurasian countries. METHODS: A survey including 20-item questionnaire was sent to experts in viral hepatitis...
December 4, 2017: Antiviral Research
https://www.readbyqxmd.com/read/29208530/analytical-performances-of-simultaneous-detection-of-hiv-1-hiv-2-and-hepatitis-c-specific-antibodies-and-hepatitis-b-surface-antigen-hbsag-by-multiplex-immunochromatographic-rapid-test-with-serum-samples-a-cross-sectional-study
#17
Leman Robin, Ralph-Sydney Mboumba Bouassa, Zita Aleyo Nodjikouambaye, Laura Charmant, Mathieu Matta, Sylvie Simon, Mounir Filali, Souleymane Mboup, Laurent Bélec
BACKGROUND: The HIV/HCV/HBsAg Triplex consists in manually performed, visually interpreted, lateral flow, immunochromatographic rapid diagnostic test simultaneously detecting in 15min human immunodeficiency virus (HIV)-1 and HIV-2 and hepatitis C virus (HCV)- specific antibodies (Ab) (IgG and IgM) and hepatitis B virus (HBV) surface antigen (HBsAg) in serum, plasma and whole blood. METHODS: A hospital-based cross-sectional study was conducted on a prospective panel of serum samples from adult inpatients included from routine analysis irrespectively of age and sex, including 250 sera positive for HIV-1-specific Ab, 250 for HCV-specific Ab, 250 for HBsAg and 250 sera negative for HIV- and HCV- Ab and HBsAg, and from 110 HIV-2-infected patients living in Ivory Coast, according to the results obtained by the reference chemiluminiscent microparticle immunoassay (CMIA) Abbott Architect i2000SR analyzer (Abbott Diagnostic, Chicago, IL, USA)...
December 5, 2017: Journal of Virological Methods
https://www.readbyqxmd.com/read/29201774/hepatitis-action-plan-and-changing-trend-of-liver-disease-in-japan-viral-hepatitis-and-nonalcoholic-fatty-liver-disease
#18
REVIEW
Tatsuya Kanto, Sachiyo Yoshio
In Japan, the estimated number of chronic hepatitis B virus infections was 1.1 to 1.4 million, and that of chronic hepatitis C virus was 1.9 to 2.3 million in 2000. The mortality of hepatocellular carcinoma had been increasing and hit the peak at around 2002, which subsequently started to decrease. Japan has a national action plan for addressing viral hepatitis called Basic Act on Hepatitis Measures, established in 2009. In 2011, basic guidelines for promotion of control measures for hepatitis were issued, comprising nine principles in order to promote measures to prevent hepatitis B and C...
January 2017: Euroasian journal of hepato-gastroenterology
https://www.readbyqxmd.com/read/29198562/disease-burden-and-costs-from-excess-alcohol-consumption-obesity-and-viral-hepatitis-fourth-report-of-the-lancet-standing-commission-on-liver-disease-in-the-uk
#19
REVIEW
Roger Williams, Graeme Alexander, Iain Armstrong, Alastair Baker, Neeraj Bhala, Ginny Camps-Walsh, Matthew E Cramp, Simon de Lusignan, Natalie Day, Anil Dhawan, John Dillon, Colin Drummond, Jessica Dyson, Graham Foster, Ian Gilmore, Mark Hudson, Deirdre Kelly, Andrew Langford, Neil McDougall, Petra Meier, Kieran Moriarty, Philip Newsome, John O'Grady, Rachel Pryke, Liz Rolfe, Peter Rice, Harry Rutter, Nick Sheron, Alison Taylor, Jeremy Thompson, Douglas Thorburn, Julia Verne, John Wass, Andrew Yeoman
This report contains new and follow-up metric data relating to the eight main recommendations of the Lancet Standing Commission on Liver Disease in the UK, which aim to reduce the unacceptable harmful consequences of excess alcohol consumption, obesity, and viral hepatitis. For alcohol, we provide data on alcohol dependence, damage to families, and the documented increase in alcohol consumption since removal of the above-inflation alcohol duty escalator. Alcoholic liver disease will shortly overtake ischaemic heart disease with regard to years of working life lost...
November 28, 2017: Lancet
https://www.readbyqxmd.com/read/29182638/respondent-driven-sampling-for-identification-of-hiv-and-hcv-infected-people-who-inject-drugs-and-men-who-have-sex-with-men-in-india-a-cross-sectional-community-based-analysis
#20
Sunil S Solomon, Allison M McFall, Gregory M Lucas, Aylur K Srikrishnan, Muniratnam S Kumar, Santhanam Anand, Thomas C Quinn, David D Celentano, Shruti H Mehta
BACKGROUND: A major barrier to achieving ambitious targets for global control of HIV and hepatitis C virus (HCV) is low levels of awareness of infection among key populations such as men who have sex with men (MSM) and people who inject drugs (PWID). We explored the potential of a strategy routinely used for surveillance in these groups, respondent-driven sampling (RDS), to be used as an intervention to identify HIV- and HCV-infected PWID and MSM who are unaware of their status and those who are viremic across 26 Indian cities at various epidemic stages...
November 2017: PLoS Medicine
keyword
keyword
90225
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"